Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Jonas Wohlfarth"'
Autor:
Jonas Wohlfarth, Corinna Kosnopfel, Dominic Faber, Marion Berthold, Claudia Siedel, Melissa Bernhardt, Andreas Schlosser, Tyler Aprati, David Liu, David Schrama, Roland Houben, Dirk Schadendorf, Matthias Goebeler, Svenja Meierjohann, Bastian Schilling
Publikováno v:
Molecular Oncology, Vol 18, Iss 10, Pp 2449-2470 (2024)
Immunotherapy has achieved tremendous success in melanoma. However, only around 50% of advanced melanoma patients benefit from immunotherapy. Cyclin‐dependent kinase inhibitor 2A (CDKN2A), encoding the two tumor‐suppressor proteins p14ARF and p16
Externí odkaz:
https://doaj.org/article/329322a45f3c4cab9aaa97867023c73c
Susceptibility of Melanoma Cells to Targeted Therapy Correlates with Protection by Blood Neutrophils
Autor:
Simone Wendlinger, Jonas Wohlfarth, Claudia Siedel, Sophia Kreft, Teresa Kilian, Sarah Junker, Luisa Schmid, Tobias Sinnberg, Ulrich Dischinger, Markus V. Heppt, Kilian Wistuba-Hamprecht, Friedegund Meier, Luise Erpenbeck, Elsa Neubert, Matthias Goebeler, Anja Gesierich, David Schrama, Corinna Kosnopfel, Bastian Schilling
Publikováno v:
Cancers, Vol 16, Iss 9, p 1767 (2024)
Elevated levels of peripheral blood and tumor tissue neutrophils are associated with poorer clinical response and therapy resistance in melanoma. The underlying mechanism and the role of neutrophils in targeted therapy is still not fully understood.
Externí odkaz:
https://doaj.org/article/5b334516b1c449d490ecb69a2fc1f8b3
Autor:
Corinna Kosnopfel, Simone Wendlinger, Heike Niessner, Johannes Siewert, Tobias Sinnberg, Angelika Hofmann, Jonas Wohlfarth, David Schrama, Marion Berthold, Claudia Siedel, Birgit Sauer, Aarthi Jayanthan, Georg Lenz, Sandra E. Dunn, Bastian Schilling, Birgit Schittek
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 42, Iss 1, Pp 1-14 (2023)
Abstract Background The mitogen-activated protein kinase (MAPK) signaling pathway is frequently hyperactivated in malignant melanoma and its inhibition has proved to be an efficient treatment option for cases harboring BRAFV600 mutations (BRAFMut). H
Externí odkaz:
https://doaj.org/article/0723a98be8b54729b41f40fee5a42d27
Autor:
Simone Wendlinger, Jonas Wohlfarth, Sophia Kreft, Claudia Siedel, Teresa Kilian, Ulrich Dischinger, Markus V. Heppt, Kilian Wistuba-Hamprecht, Friedegund Meier, Matthias Goebeler, Dirk Schadendorf, Anja Gesierich, Corinna Kosnopfel, Bastian Schilling
Publikováno v:
Cancers, Vol 14, Iss 9, p 2294 (2022)
Background: Eosinophils appear to contribute to the efficacy of immunotherapy and their frequency was suggested as a predictive biomarker. Whether this observation could be transferred to patients treated with targeted therapy remains unknown. Method
Externí odkaz:
https://doaj.org/article/079e7654b5804f77bece4aa0a4ee0017
Autor:
Maike Haußmann, Marc Schmidt, Helga Sennefelder, Mareike D. Maler, Jonas Wohlfarth, Matthias Goebeler, Stefan F. Martin, Christian Adam, Annette Rodin
Publikováno v:
Journal of Investigative Dermatology. 137:367-376
Chromium allergy is a common occupational skin disease mediated by chromium (VI)-specific T cells that induce delayed-type hypersensitivity in sensitized individuals. Additionally, chromium (VI) can act as an irritant. Both responses critically requi
Autor:
Selma Ugurel, Jonas Wohlfarth, Ivelina Spassova, Cathrin Ritter, Angela Cherouny, Jürgen C. Becker, Antje Sucker, Christina Drusio, Lisa Zimmer, Anita Melior, Dirk Schadendorf
Publikováno v:
Cancer immunology, immunotherapy : CII. 68(6)
Merkel cell carcinoma (MCC) is an aggressive skin cancer in which PD-1/PD-L1 blockade has shown remarkable response rates. However, a significant proportion of patients shows primary or secondary resistance against PD-1/PD-L1 inhibition, with HLA cla